Prime Highlights:

• ImmuPharma is in talks with several major pharmaceutical companies, including some of the world’s top ten, for its P140 autoimmune programme.
• The company is focused on securing the best partner for P140, prioritizing a careful approach to maximize the treatment’s potential.

Key Facts:

• ImmuPharma’s strengthened financial position now allows it to operate well into the final quarter of 2026, with no immediate plans to raise additional funds.
• Several potential partners have signed confidentiality agreements, enabling detailed technical and commercial evaluations of P140.

Background:

ImmuPharma PLC (AIM:IMM) has announced that several leading pharmaceutical companies, including members of the world’s top ten, are in discussions regarding its P140 autoimmune treatment programme.

A number of these potential partners have already signed confidentiality agreements, allowing for more detailed technical and commercial evaluations. Discussions cover scientific, manufacturing, and business considerations, as is typical during partnership negotiations. These talks often involve thorough due diligence and in-depth review of clinical data before formal proposals are made.

The company emphasized its goal of finding the “best fit” partner to advance and commercialize P140, a treatment it says represents a novel approach to diagnosing and treating autoimmune conditions. While ImmuPharma had initially aimed to complete a deal by the end of 2025, the board now expects the timeline to extend, with completion anticipated in 2026.

Tim McCarthy, Chief Executive, said the company is pleased with the interest shown in P140. He added that the team is focused on finding the right partner to fully realize the drug’s potential, taking a careful approach to ensure the best results for shareholders.

Alongside the partnership update, ImmuPharma reported a strengthened financial position. Recent research and development tax credits, earlier exercise of share warrants, and additional proceeds from its funding arrangement with Lanstead Capital have brought total receipts from that deal to around £2 million, slightly above the original £1.875 million subscription value.

The company confirmed that it has enough cash to operate well into the final quarter of 2026 and reiterated that there are no plans to raise additional funds.

ImmuPharma said it will continue to provide updates to the market as discussions progress.